Current and future applications of the anti-IgE antibody omalizumab
Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and...
Guardado en:
Autores principales: | Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c41 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Luke F. Pennington, et al.
Publicado: (2016) -
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Pascal Gasser, et al.
Publicado: (2020) -
Two decades with omalizumab: what we still have to learn
por: Incorvaia C, et al.
Publicado: (2018) -
Development and characterization of a unique anti‐IgE mouse monoclonal antibody cross‐reactive between human and canine IgE
por: Akiko Kumagai, et al.
Publicado: (2021) -
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
por: J. M. Orengo, et al.
Publicado: (2018)